OC-0929 How to manage consolidative radiotherapy after HD methotrexate in PCNSL patients: a phase II study.

MLA

Chiesa, S., et al. “OC-0929 How to Manage Consolidative Radiotherapy after HD Methotrexate in PCNSL Patients: A Phase II Study.” Radiotherapy & Oncology, vol. 170, May 2022, pp. S820–21. EBSCOhost, https://doi.org/10.1016/S0167-8140(22)02709-8.

APA

Chiesa, S., Beghella Bartoli, F., Mazzarella, C., Hohaus, S., Cannatà, M. C., Catucci, F., D’Alò, F., Bracci, S., Nardangeli, A., Martino, A., Dinapoli, N., Marazzi, F., Manfrida, S., Gambacorta, M. A., Aristei, C., Valentini, V., & Balducci, M. (2022). OC-0929 How to manage consolidative radiotherapy after HD methotrexate in PCNSL patients: a phase II study. Radiotherapy & Oncology, 170, S820–S821. https://doi.org/10.1016/S0167-8140(22)02709-8

Chicago

Chiesa, S., F. Beghella Bartoli, C. Mazzarella, S. Hohaus, M.C. Cannatà, F. Catucci, F. D’Alò, et al. 2022. “OC-0929 How to Manage Consolidative Radiotherapy after HD Methotrexate in PCNSL Patients: A Phase II Study.” Radiotherapy & Oncology 170 (May): S820–21. doi:10.1016/S0167-8140(22)02709-8.